Interestingly, in line with our in vitro findings, gene expression analyses on publicly available CRC patient clinical datasets and mouse intestinal organoids derived from a preclinical CRC mouse model reveal KRAS mutation‐dependent upregulation of the selected AATs (Fig. 7D–F and Fig. S7A–C, respectively). Here, KRAS is linked to colorectal carcinoma.